Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Copy Top Investors Portfolio
Crypto Technical Analysis
Chart Pattern Signal

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AZN
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
AZN
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

AZN Price Prediction Next Week

Based on the provided data and current market conditions, here's a comprehensive analysis for AstraZeneca (AZN) for the next trading week:

Technical Analysis

The technical indicators show AZN is currently trading around $66.67, with key support at $64.93 and resistance at $68.94. The RSI at 63.37 indicates the stock is approaching overbought territory but still has room to run. The positive MACD of 0.38 suggests bullish momentum.

News Sentiment Analysis

Several significant developments are likely to impact AZN's price next week:

  1. Major Investment in Canada:
  • Announced CA$820 million ($570 million) investment
  • Creating 700+ new jobs
  • Supporting expansion in greater Toronto area
  • Positive impact on long-term growth strategy
  1. China Operations Concerns:
  • Recent executive investigations in China
  • Potential sales impact in one of its key markets
  • Management restructuring underway
  1. Pipeline Development:
  • Multiple late-stage clinical trial readouts expected in 2025
  • Potential $25 billion in sales from pipeline opportunities

Price Projection for Next Week

Based on technical and fundamental factors:

Target Prices:

  • Bullish scenario: $68.94 (Fibonacci R1)
  • Base case: $66.93 (Fibonacci pivot)
  • Bearish scenario: $64.93 (Fibonacci S1)

Probability:

  • Bullish: 40% - Supported by strong Canada investment news and pipeline potential
  • Base: 35% - Balanced by mixed technical indicators
  • Bearish: 25% - Limited downside due to current valuation levels

Trading Recommendation

SELL with a target price of $64.93

Rationale:

  1. China operations uncertainty creates near-term headwinds
  2. RSI approaching overbought levels
  3. Recent price action suggests potential pullback
  4. Technical indicators showing resistance ahead

Set stop-loss at $68.94 (Fibonacci R1) to limit potential losses.

Based on the provided data and current market conditions, here's a comprehensive analysis for AstraZeneca (AZN) for the next trading week:

Technical Analysis

The technical indicators show AZN is currently trading around $66.67, with key support at $64.93 and resistance at $68.94. The RSI at 63.37 indicates the stock is approaching overbought territory but still has room to run. The positive MACD of 0.38 suggests bullish momentum.

News Sentiment Analysis

Several significant developments are likely to impact AZN's price next week:

  1. Major Investment in Canada:
  • Announced CA$820 million ($570 million) investment
  • Creating 700+ new jobs
  • Supporting expansion in greater Toronto area
  • Positive impact on long-term growth strategy
  1. China Operations Concerns:
  • Recent executive investigations in China
  • Potential sales impact in one of its key markets
  • Management restructuring underway
  1. Pipeline Development:
  • Multiple late-stage clinical trial readouts expected in 2025
  • Potential $25 billion in sales from pipeline opportunities

Price Projection for Next Week

Based on technical and fundamental factors:

Target Prices:

  • Bullish scenario: $68.94 (Fibonacci R1)
  • Base case: $66.93 (Fibonacci pivot)
  • Bearish scenario: $64.93 (Fibonacci S1)

Probability:

  • Bullish: 40% - Supported by strong Canada investment news and pipeline potential
  • Base: 35% - Balanced by mixed technical indicators
  • Bearish: 25% - Limited downside due to current valuation levels

Trading Recommendation

SELL with a target price of $64.93

Rationale:

  1. China operations uncertainty creates near-term headwinds
  2. RSI approaching overbought levels
  3. Recent price action suggests potential pullback
  4. Technical indicators showing resistance ahead

Set stop-loss at $68.94 (Fibonacci R1) to limit potential losses.

AZN Similar Chart Price Prediction

The price of AZN is predicted to go up 1.18%, based on the high correlation periods with CUBE. The similarity of these two price pattern on the periods is 90.92%.

stocks logo

AZN

stocks logo

CUBE

Up: 1.18%Similarity: 90.92%

AZN Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030

Year

AZN Price Forecast($)

Potential Return(%)

2025

75.000

13.210

2026

66.590

0.510

2027

89.000

34.340

2028

95.000

43.400

2029

95.000

42.130

2030

120.000

79.530

What is AZN stock price prediction 2025 ?

AZN stock is predicted to reach $75 by the end of 2025, reflecting a potential 12% upside from its current price of $66.8. This projection is based on AstraZeneca's strong pipeline in oncology and weight-loss therapies, coupled with its ambitious revenue target of $80 billion by 2030. However, risks from the ongoing investigation in China may limit short-term growth.

What is AZN stock price prediction 2026 ?

AZN's stock price is currently $66.59. Based on its diversified pipeline, strong oncology segment, and projected revenue growth, analysts estimate a potential price of $89.20 by 2026, reflecting a 34% upside. However, uncertainties in the Chinese market and regulatory risks could limit this growth.

What is AZN stock price prediction 2027 ?

AZN's stock price in 2027 is projected to reach approximately $89-$95, driven by its robust pipeline, diversified portfolio, and ambitious revenue target of $80 billion by 2030. The company's focus on oncology, rare diseases, and weight management, alongside geographical expansion, supports long-term growth. However, risks like the China investigation and competitive pressures could moderate this trajectory.

What is AZN stock price prediction 2028 ?

AZN stock is predicted to reach approximately $95 by 2028. This projection is based on AstraZeneca's strong revenue growth trajectory, driven by its oncology and biopharmaceutical segments, and its ambitious target of $80 billion in revenue by 2030. However, risks such as geopolitical challenges in China and competitive pressures in weight-loss therapies could impact this forecast.

What is AZN stock price prediction 2029 ?

AZN stock is projected to reach approximately $95 by 2029, driven by its robust pipeline in oncology, biopharmaceuticals, and rare diseases, alongside its ambitious revenue target of $80 billion by 2030. The company's strong financial growth trajectory, coupled with strategic investments in key markets like the U.S. and Spain, supports this forecast. However, risks such as geopolitical challenges in China may temper growth potential.

What is AZN stock price prediction 2030 ?

AZN stock is projected to reach approximately $120 by 2030, driven by its ambitious $80 billion revenue target and strong growth in oncology, biopharmaceuticals, and rare diseases. This forecast assumes a compound annual growth rate (CAGR) of around 10% from its current price of $66.94, supported by pipeline advancements and geographical expansion. However, risks such as regulatory challenges in China and competition in weight-loss therapies could impact this trajectory.

AZN Revenue Forecast

AZN EPS Forecast

AZN FAQs

What is bull’s view on AZN?

AstraZeneca (AZN) is currently trading at $66.26, with analysts projecting a 12-month target price of $89.20, indicating a potential upside of 35%. This bullish outlook is driven by strong revenue growth across its oncology and biopharmaceutical segments, alongside promising weight-loss drug candidates in its pipeline. However, uncertainties in China due to ongoing investigations could pose short-term risks.

What is bear's view on AZN?

AstraZeneca (AZN) stock currently faces bearish sentiment due to uncertainties in its Chinese market operations, including an ongoing investigation, which could impact sales in one of its key regions. The stock is trading at $66.26, with resistance near $67.29 and support at $64.31, reflecting limited upside in the short term. Additionally, its RSI of 47.77 suggests neutral momentum, but the lack of strong catalysts and geopolitical risks weigh on its near-term outlook.

What is AZN revenue forecast for next quarter？

The market consensus for AZN's revenue in the upcoming quarter is projected to be approximately $13.237B USD.

What is AZN eps forecast for next quarter？

The market consensus for AZN's eps in the upcoming quarter is projected to be approximately $1.068 USD.

AZN VS S&P500

The company is expanding its oncology presence with several important pipeline products. In particular, the company's EGFR drug Tagrisso looks well positioned to drive major cashflows over the next decade.

The management team is focusing the pipeline toward areas of high unmet medical need, which should increase the odds of success and bring strong pricing power for the new drugs.

AstraZeneca has a large presence in emerging markets and should benefit from these markets' fast growth prospects.

Ask Intellectia about AZN

AZN Analyst's Forecast

Matthew Weston

UBS

Strong Sell → Hold

Price Target

n/a

Upside

0%

UBS upgraded AstraZeneca to Neutral from Sell with an unchanged price target of 11,300 GBp. The firm cites the stock's 24% decline over the past three months amid China government investigations and "disappointing" data on Dato-DXd lung potential for the upgrade. While significant China uncertainty, but wholesale loss of AstraZeneca's franchise seems unlikely, the analyst tells investors in a research note.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2024 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free